Endo says CFO, COO to leave the company; Lilly sues Perrigo for challenging Axiron patent;

@FiercePharma: U.K. cost watchdog about-faces on BMS and AZN's Forxiga, recommending it for some diabetes patients. Story | Follow @FiercePharma

@EricPFierce: Will Hospira never learn? FDA warning letter says some problems at India plant same as those recently noted at Rocky Mount. More | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: FDA is importing TPN to ease drug shortage. Story | Follow @CarlyHFierce

> Endo Health Solutions ($ENDP) said two of its top executives, CFO Alan G. Levin and COO Julie McHugh, are leaving the company; no replacements have yet been named. Release | Report

> Eli Lilly ($LLY) sued Perrigo ($PRGO) for infringing its patent on the low-testosterone treatment Axiron, seeking to block generic versions of the drug. Report

> Pfizer ($PFE) issued $4 billion in bonds, in its first dollar-denominated debt issue since 2009. Report

> Analysts hiked their price targets on Valeant Pharmaceuticals ($VRX) on the strength of its newly agreed acquisition of Bausch + Lomb. Report

> Royalty Pharma contends that recent stock sales by Elan ($ELN) investors signal that shareholders support its buyout proposal. Report

> Germany's Stada Arzneimittel said it successfully placed €350 million worth of corporate bonds. Report

Medical Device News

@FierceMedDev: GE snags ultrasound repair business. More | Follow @FierceMedDev

 @DamianFierce: As GSK trumpets two new FDA approvals, France's bioMérieux is poised to cash in on companion diagnostics. More | Follow @DamianFierce

@MichaelGFierce: Devicemakers balk at FDA's recall guidelines. Item | Follow @MichaelGFierce

> Sequenom reaches into France with prenatal Dx. Report

> GE snags ultrasound repair business. Article

> Devicemakers balk at FDA's recall guidelines. More

> Edwards hit with FDA warning letter. News

> Abbott's Absorb takes India by storm. Story

Biotech News

@FierceBiotech: UCLA slams the door on GlaxoSmithKline's latest R&D competition. More | Follow @FierceBiotech

@JohnCFierce: ICYMI: Updated: GlaxoSmithKline gains FDA OK on two genetically targeted melanoma drugs. Report | Follow @JohnCFierce

@RyanMFierce: Biogen Idec appears to be playing the long game with delayed EU launch of Tecfidera, and that could benefit even short-term investors. | Follow @RyanMFierce

 @EmilyMFierce: Newest feature at @FierceBiotech: Top 10 experimental cancer drugs - 2013. Special Report | Follow @EmilyMFierce

> San Diego biotech files $23M IPO for gastroparesis PhIII. Report

> Pfizer taps UCSF for small-molecule drug discovery. Story

> ASCO presentations portend future shock of immunotherapy drug prices. Article

> Elan execs ready fallback plan as Royalty attacks 'jumble' of deals. News

Pharma Manufacturing News

> Pfizer sells King Pharma plant to UPM Pharmaceuticals. More

> UCB sells New York plant to Unither. News

> FDA turns to Fresenius to help relieve TPN shortage. Story

> New problems with Hospira's Indian plant reminiscent of Rocky Mount. Article

> J&J appeals OTC plant license revocation in India. Item

Vaccines News

> H7N9 shows resistance to Roche's Tamiflu. News

> Chinese HFMD vaccine impresses in Phase III. Report

> Gates-inspired gene therapy gives pandemic protection. Story

> Study links GSK's swine flu vaccine to narcolepsy in adults. Article

> Researchers seek fresh approach to HIV vaccine. More

And Finally... A new analysis from the American Medical Association found that children who have used ADHD treatments are no less likely to abuse drugs later in life than those who haven't. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.